SEC Tracker
Get the app

Strata Critical Medical SRTA

Strata Critical Medical reported Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue increased 50.3% year-over-year to $74.1 million
  2. Q3 2026 net loss from continuing operations of $(7.6) million
  3. Adjusted EBITDA of $9.6 million in Q3 2026
  4. Announced $20 million share repurchase authorization

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Strata Critical Medical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release with details on revenue, net loss, and adjusted EBITDA.
  2. The press release is incorporated by reference in the Form 8-K.
  3. Revenue for Q3 2026 increased 50.3% year-over-year to $74.1 million.
  4. Clinical revenue rose 20.3% sequentially in Q3 2026 compared to Q2 2026.
  5. The company reported a net loss from continuing operations of $(7.6) million, or (10.3)% of revenue.
  6. Adjusted EBITDA for Q3 2026 was $9.6 million, with a margin of 13.0%.
  7. Cash flow from operating activities was $9.5 million, and free cash flow was $8.6 million.
  8. Strata also announced a $20 million share repurchase authorization.

8 of 8 claims matched the filing text.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 3, 2026, Strata Critical Medical, Inc. ("Strata") issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K1 and is incorporated by reference herein2.

This information is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:

Exhibit No.

Description

99.1

Press Release, dated November 3, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STRATA CRITICAL MEDICAL, INC.

Dated: November 3, 2026

By:

/s/ William A. Heyburn

Name:

William A. Heyburn

Title:

Co-Chief Executive Officer and Chief Financial Officer

November 3, 2026

Strata Critical Medical Announces Third Quarter 2026 Results

• Revenue increased 50.3% year-over-year to $74.1 million in Q3 20263 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 20264 • Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenue5 • Adjusted EBITDA (1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0%6 • Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow (1) was $8.6 million in Q3 20267

• Announced $20 million share repurchase authorization8; will be deployed along with continued M&A strategy execution

NEW YORK — (November 3, 2026) — Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.

GAAP FINANCIAL RESULTS

(in thousands except percentages, unaudited)

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 % Change 2026 2025 % Change Revenue: Logistics $ 44,899 $ 46,507 (3.5) % $ 140,738 $ 127,563 10.3 % Transplant Clinical 15,217 1,199 NM (2) 37,577 1,199 NM (2) Other Clinical 13,965 1,592 NM (2) 35,656 1,592 NM (2) Total Clinical 29,182 2,791 NM (2)

7

Similar companies

Companies of similar size in SIC 8000 and related industry codes: the same peer list as the financial tables.

  1. Talkspace TALK public float $393M, Jun 30, 2025
  2. DocGo DCGO public float $150M, Jun 30, 2025
  3. InnovAge Holding INNV public float $111M, Dec 31, 2025
  4. U S Physical Therapy USPH public float $737M, Jun 30, 2025
  5. LifeStance Health Group LFST public float $817M, Jun 30, 2025